Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 0.24
- Piotroski Score 7.00
- Grade Equal-Weight
- Symbol (LZ)
- Company LegalZoom.com, Inc.
- Price $7.67
- Changes Percentage (0.46%)
- Change $0.04
- Day Low $7.59
- Day High $7.75
- Year High $13.74
LegalZoom.com, Inc. operates an online platform for legal and compliance solutions in the United States. The company's platform offers products and services, including business formations, creating estate planning documents, protecting intellectual property, completing certain forms and agreements, providing access to independent attorney advice, and connecting customers with experts for tax preparation and bookkeeping services. It serves small businesses and individuals. LegalZoom.com, Inc. was incorporated in 1999 and is headquartered in Glendale, California.
- Last Earnings 06/30/2011
- Ex-Dividend for 5/16 Dividend 08/08/2011
- Dividend Payable 09/09/2011
- Today N/A
- Next Earnings (Estimated) 02/20/2025
- Fiscal Year End N/A
- Average Stock Price Target $11.50
- High Stock Price Target $20.00
- Low Stock Price Target $8.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.10
- Trailing P/E Ratio 84.1
- Forward P/E Ratio 84.1
- P/E Growth 84.1
- Net Income $13.95 M
Income Statement
Quarterly
Annual
Latest News of LZ
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Cubs add prospect Owen Caissie to 40-man roster, DFA ex-closer Adbert Alzolay
The Chicago Cubs added Owen Caissie to their 40-man roster, showcasing his potential. Uncertainty remains about his position, amidst a roster reshuffle. The Cubs aim to balance established talent with...
By The New York Times | 1 day ago -
EXCLUSIVE: Alzamend Neuro Reveals Full Data From Nonclinical Study Of Its Lead Alzheimer's Drug Potential
Alzamend Neuro has completed a study comparing AL001 and lithium carbonate in Alzheimer's mice, showing potential advantages of AL001 at low doses. This could offer safer long-term treatment options f...
By Yahoo! Finance | 2 days ago -
Needham downgrades Biogen on slow growth of Alzheimer's drug
Needham downgraded Biogen Inc due to slower growth of Alzheimer's drug, Leqembi, and lack of major catalysts in the next year. The brokerage reduced revenue estimates for Leqembi and mentioned potenti...
By Yahoo! Finance | 2 days ago
